Clinical Trials Browser

Phase 2 × mirvetuximab soravtansine × 1 year × Clear all

NCT06890338 2026-02-24

A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.

Phase 2 Recruiting

140 enrolled

Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms

NCT05041257 2026-01-09

PICCOLO

Phase 2 Completed

79 enrolled 14 charts

Gynecologic

Fallopian Tube Neoplasms, Neoplasms, Ovarian Neoplasms

NCT06682988 2026-01-09

A Study to Assess Adverse Events and Change in Disease Activity in Participants With Platinum-Resistant Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression Treated With Intravenously (IV) Infused Mirvetuximab Soravtansine

Phase 2 Recruiting

110 enrolled

Gynecologic

Fallopian Tube Neoplasms

NCT06365853 2025-12-18

A Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Participants With Recurrent Ovarian Cancer With High Folate Receptor-Alpha Expression

Phase 2 Recruiting

100 enrolled

Gynecologic

Ovarian Neoplasms

NCT05887609 2025-10-30

An Evaluation of Maintenance Therapy Combination Mirvetuximab Soravtansine and Olaparib

Phase 2 Recruiting

53 enrolled

Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT05456685 2025-10-28

Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FRα) Expressing, Platinum-sensitive Epithelial Ovarian Cancer

Phase 2 Active not recruiting

125 enrolled

Gynecologic

Fallopian Tube Neoplasms, Neoplasms, Ovarian Neoplasms

NCT04606914 2025-09-08

Study of Carboplatin and Mirvetuximab Soravtansine in First-Line Treatment of Patients Receiving Neoadjuvant Chemotherapy With Advanced-Stage Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Phase 2 Recruiting

70 enrolled

Gynecologic

Ovarian Neoplasms

NCT03832361 2025-07-18

Evaluation of Mirvetuximab Soravtansine (IMGN853) in Women With Folate Receptor-α Positive Endometrial Cancer

Phase 2 Recruiting

50 enrolled

Gynecologic

Endometrial Neoplasms

NCT03835819 2025-05-15

A Phase 2 Study of Mirvetuximab Soravtansine (IMGN853) and Pembrolizumab in Endometrial Cancer (EC)

Phase 2 Active not recruiting

18 enrolled 17 charts

Gynecologic

Endometrial Neoplasms

NCT04274426 2025-04-06

MIROVA

Phase 2 Active not recruiting

136 enrolled

Gynecologic

Recurrent Epithelial Ovarian, Fallopian or Peritoneal Carcinoma